Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025.
As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025.
What's Your Reaction?
